INTRODUCTION
============

The Thoroughbred which is best known for horse racing is a relatively recent horse breed derived from a small number of Arabian stallions and native British mares in 17th and 18th century England ([@b10-ajas-28-6-771]). To measure horse racing performance, various phenotypic values are used including race time, best race time, rank, position rates, annual earnings, and earnings per start. In particular, race time for each race is the most direct measure of speed and hence, makes it a suitable quantitative measure for evaluating the genetics of racing performance ([@b21-ajas-28-6-771]; [@b26-ajas-28-6-771]). In a horse breeding study, race time showed moderate heritability in the range of 0.1 to 0.3 ([@b23-ajas-28-6-771]), with higher heritability for shorter distance race time. Previously, a study of 12,279 racehorses registered in the Korea Racing Authority (KRA), adjusted race time showed a 0.324 heritability ([@b28-ajas-28-6-771]). However, as racing Thoroughbreds have multiple records for race time under different conditions and environmental factors, race time alone is not suitable as phenotypic value for genome-wide association studies (GWAS). But we can show racing performance of each Thoroughbred based on racing time by estimated breeding value (EBV). Originally, EBV is genetic value of complex traits which can help breeder choices. That value means how much each Thoroughbreds will pass a trait to its progeny, genetically. The EBV for racing time is single numerical value that can show racing performance of each Thoroughbred affected by only genetic effect. So we thought that EBV was suitable for GWAS as a phenotypic value.

A candidate gene approach to identify genetic variants associated with racing performance in Thoroughbreds revealed a single-nucleotide polymorphism (SNP; ECA18 g.66493737C/T) in the first intron of the equine myostatin gene (*MSTN* gene) ([@b13-ajas-28-6-771]). Several GWAS have confirmed this finding that SNPs within or near the *MSTN* gene are strongly associated with racing performance ([@b2-ajas-28-6-771]; [@b13-ajas-28-6-771]; [@b36-ajas-28-6-771]). Although MSTN variants have been reported to be highly associated with horse racing performance, this complex trait is more likely to be polygenic in nature. In the case of human athletic performance, more than 220 genes were reported to be associated with the phenotype ([@b4-ajas-28-6-771]). Similarly, we speculate that other SNPs not-related to MSTN could be associated with racing performance in Thoroughbreds.

To identify the genetic basis of horse racing performance, we used the EBV of race time as the phenotype for GWAS and conducted a joint-analysis of two-stage GWAS to search for significant genetic variants associated with race time. The EBV was used as the phenotype as it only considers the genetic component of phenotypic variance, increasing the statistical power of the analysis. In the first stage of GWAS, a relatively large number of markers were evaluated in a relatively small number of samples. In the second stage, a relatively small number of markers identified as having large effects in the first stage were evaluated in a relatively large number of samples. This joint analysis of two-stage GWAS has been shown to increase the power to detect genetic association ([@b31-ajas-28-6-771]; [@b32-ajas-28-6-771]). Using this approach, we identified 28 SNPs to be associated with the Thoroughbred racing performance. The SNPs were related to 17 genes including genes for myogenesis and muscle maintenance.

MATERIALS AND METHODS
=====================

Ethics and blood collection
---------------------------

Korea Racing Authority has established an animal experimentation ethics committee according to the Animals Protection Act 14 of Korea. This committee, titled Korea Racing Authority Institutional Animal Care and Use Committee (KRA IACUC) is composed of two external members and three internal members. One external member is a research veterinarian with experience in experimental animals (Veterinarian Act 2, paragraph 1, in Korea) and the other member is from an animal protection organization (Animals Protection Act 14, paragraph 2, in Korea). Three internal members are composed of the general manager (Chairman of KRA IACUC) and senior managers of the Equine Health and Welfare Section and the Disease Control and Prevention Section of the veterinary Center of KRA. KRA IACUC is under the auspices of the Equine Health and Welfare section of veterinary Center of KRA. The committee operates on a regular basis rather than approving each blood collection as blood collection of the race horses are performed routinely before every race. The KRA operates experimental procedures including drug testing and ethics problem according to international guidelines, which is guaranteed by an affiliate association of the Korean government (KRA Act, Article 44) and is a member of the Association of Official Racing Chemist (AORC). In addition, the owners of the horses in KRA have granted permission for blood extraction for research and development purposes (KRA Act, Article 11, 12, 36).

Genomic DNA of the Thoroughbreds was isolated from blood collected for drug testing, health care and horse bloodlines management by the KRA. Legally, 25 mL of blood, divided into three heparin tubes must be collected from the carotid artery of all race horses participating in the race 2 to 3 hours before the race. The samples are stored at KRA, and two samples are used in drug testing, while the third sample is stored for either DNA identification or for additional drug testing. After the race, urine is collected from horses with high standing in the race for primary drug testing. If prohibited drugs are discovered in the urine, the third sample of blood collected before the race is used for secondary drug testing. From an animal welfare point of view, drug testing protects the racehorse from use of prohibited drugs for enhanced racing performance.

The DNA information from the collected blood is used to preserve horse bloodlines and used in the genetic improvement of horse by genetic methods. With the development of genomics, horse breeding and selection strategies are moving towards the use of SNP information derived from genomic DNA. So KRA uses archived blood samples of racehorses that passed the dope test both before and after the race.

For imported stallions and retired racehorses of KRA that do not participate in races, 10 mL of blood was collected for DNA extraction. The collection of blood from these horses was approved as routine procedures for DNA information storage and horse bloodline management. Detailed records related to blood collection are outlined in [Supplementary Table 2](#s1-ajas-28-6-771){ref-type="supplementary-material"}. The genotyping SNPs in this study was conducted for the dual purpose of academic achievement and horse preservation within the legal and ethical framework. All blood-collection was performed by KRA veterinarians.

Estimated breeding value of race time
-------------------------------------

To improve the accuracy of the EBV, we simplified the animal model by reducing the factors deemed unnecessary (racing year, racing type, and type of weight carried). A multiple-record animal model was used to estimate the genetic parameters as breeding value. The animal model used in this study is as follows:
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where Y = the vector of observations, b = the vector of fixed effects, v = the vector of random effects, pe = the vector of permanent environmental effect: common environment, a = the vector of individual additive genetic effect, Z = relationship matrix and e = the vector of residual error. X, W1, W2, and Z are coefficient matrices for b, v, pe, and a, respectively.

Observations comprised a total of 262,326 race time records from 14,752 Thoroughbreds between 1994 and 2010 at Seoul Racecourse, Busan-Gyeongnam Racecourse of the KRA. The fixed effects used were racecourse, racing distance, country of foaling, sex, and age. Racing distances in the KRA were 1,000, 1,200, 1,300, 1,400, 1,600, 1,700, 1,800, 1,900, 2,000, 2,200, and 2,300 m. Countries of foaling were divided into Korea or others with sex divided into female, male, or gelding. Random effects were moisture, jockey, weight of handicap, and trainer. Different performances in a common environment represented the difference between the repeatability and heritability. Repeatability was explained by the permanent environment of the horse during the rearing period. The relationship matrix Z included all animal racers, non-racers, reproducers, and non-reproducers. The vector of the individual genetic effect, EBV, is the coefficients vector of Z matrix. Residual error, e, represent inexplicable factors such as temporary environmental effects (e.g., racing strategy, race condition, etc.).

All parameters were estimated using the ASREML program (Gilmour, 2000) facilitated by the derivative-free restricted maximum likelihood method for a single-trait animal model. Using this model, we calculated the EBV for race time.

Initial genome-wide scan: stage 1
---------------------------------

DNA samples were obtained from a total of 240 Thoroughbreds registered in the KRA. The 180 racehorses and 60 stallions were genotyped for the initial genome-wide scan using EquineSNP50 Genotyping BeadChips (Illumina, San Diego, CA, USA). The chip includes 54,602 SNPs that are uniformly distributed on the 31 equine autosomes and X chromosome (average density of 1 SNP per approximately 43 kb) from the EquCab2 SNP database of the horse genome. All samples were genotyped in the National Instrumentation Center for Environmental Management (NICEM) at Seoul National University. We excluded SNPs with a missing rate of \>0.05, minor allele frequency of \<0.05, and Hardy-Weinberg equilibrium test p-value of \<0.001. SNPs on the X chromosome were also excluded, retaining 41,371 autosomal SNPs for analysis. Association analysis of stage 1 was conducted on the basis of linear regression using the software PLINK ([@b29-ajas-28-6-771]).

Joint analysis in replication study: stage 2
--------------------------------------------

For stage 2 association analysis, 190 SNPs selected in stage 1 and the two SNPs (BIEC2-417495 and BIEC2-417274) related to MSTN, were included. For the replicate study, 916 Thoroughbreds with more than four race records in Korea were genotyped using the customized Equine BeadXpress SNP Chips (Illumina) at NICEM. A total of 172 SNPs were successfully genotyped on the Equine SNP chips. We applied the same quality control criteria as in stage 1 and retained 158 SNPs for further analysis. For the joint analysis, we combined the data from 158 SNPs from 240 Thoroughbreds from stage 1 and 916 Thoroughbreds from stage 2. The joint association analysis was based on linear regression implemented in PLINK. The same analyses were also conducted on the 2 SNPs related to MSTN gene. Haploview program was used to visualize several linkage disequilibrium (LD) blocks of interest regions.

RESULTS
=======

Initial genome-wide scan of 240 Thoroughbred single-nucleotide polymorphisms: stage 1
-------------------------------------------------------------------------------------

In this GWAS, we compared the genotypes of Thoroughbreds with the EBV as a phenotypic value. We conducted the initial genome-wide scan in a population of 240 Thoroughbreds. The chromosome sorting is displayed as a Manhattan plot ([Figure 1](#f1-ajas-28-6-771){ref-type="fig"}). Initial analysis of our data found 3,919 SNPs that were associated with the EBV for race time (unadjusted p-value, \<0.05), though none of these SNPs exceeded the threshold of multiple tests (p\<2.41 ×10^−6^, equivalent to p = 0.05 after Bonferroni correction). At this stage, speculation on the plausibility and biological significance of these candidate SNPs is not mature because of the inevitably high false-positive rate from several tens of thousands of tests are performed on the same data set. Replication of these findings in a larger population was required to identify significant SNPs associated with racing performance. We selected 190 SNPs that were evenly distributed on the equine chromosomes for the second stage.

Joint analysis of 1,156 Thoroughbreds for replication study: stage 2
--------------------------------------------------------------------

In the second stage, 916 additional samples were randomly selected from the Thoroughbred population of the KRA not included in stage one. To further test the association with the EBV, we genotyped 190 of the most associated SNPs from stage 1 in the 916 Thoroughbreds. After data quality control procedures, 158 SNPs were available for stage 2 for a total of 1,156 Thoroughbreds. These SNPs covered 119 distinct chromosomal regions defined by a maximal distance between two SNPs of \<100 kb. Out of the 119 regions, 92 contained only one SNP, and 27 contained more than two SNPs. In joint analysis using the combined population data, 28 SNPs (17.7% of the 158 SNPs) achieved genome-wide significance criteria (p-value = 0.000632911, equivalent to p = 0.1 after Bonferroni correction) ([Table 1](#t1-ajas-28-6-771){ref-type="table"}).

The most significant SNP (p = 8.941×10^−8^ in joint analysis), BIEC2_330691, identified by our two-stage GWAS was found on chromosome 16 with the other 11 most significant SNPs. Out of the 11 most significant SNPs, three were top-ranking and located in the sixth intron of the gene glucoside xylosyltransferase 2 (GXYLT2) (included in block 10 of [Figure 3](#f3-ajas-28-6-771){ref-type="fig"}). Twelve of the top 27 SNPs were located together, (contained seven of 119 distinct chromosomal regions), spanning a 3.61 Mb region on chromosome 16 (chr16: 14.18 to 17.79 Mb). Those regions have not been previously reported as being related to the racing performance of Thoroughbreds ([Figure 2](#f2-ajas-28-6-771){ref-type="fig"} and [Table 1](#t1-ajas-28-6-771){ref-type="table"}). Four of these 12 significant SNPs were in PDZ domain-containing ring finger 3 (*PDZRN3*) genes and other four containing BIEC2_330691 was in a 0.37-Mb interval (chr16: 17.74 to 17.79 Mb). The LD calculations were performed within the 3.6-Mb region on chromosome 16 (chr16: 14.18 to 17.79 Mb). Thirteen discrete LD blocks were identified in the 3.6-Mb peak of association on chromosome 16 ([Figure 3](#f3-ajas-28-6-771){ref-type="fig"}).

Six significant SNPs including the fourth most significant SNPs, BIEC2_569862, were located on chromosome 21. These SNPs were not located on a distinct chromosomal region but on two regions. One is chr21: 18.15 to 18.34 (2 SNPs) and another is chr21: 47.50 to 49.89 (4 SNPs). Four significant SNPs were on chromosome 20. Two SNPs were on one distinct chromosomal regions (chr20: 32.12 to 32.13, 2 SNPs) and other two were mostly near each other (chr20: 29.89 to 32.13). Three significant SNPs were dispersed in chromosome 3. Chromosome 5, 28, 30 each had one significant SNP.

Candidate genes associated with racing performance of Thoroughbreds
-------------------------------------------------------------------

The transcriptional content of 28 significant SNPs was assessed using the EquCab2.0 assembly and annotation of the horse genome. The genes were annotated using the gene IDs from ENSEMBL genome browser EquCab2 (<http://www.ensembl.org/>). We collected the genes whose entire information was located within or near (±10 kb) the SNPs. Twenty-five SNPs associated with EBV for race time belonged to 17 genes (Ensemble Gene ID) which were mainly related to muscle terms ([Table 1](#t1-ajas-28-6-771){ref-type="table"}). Twenty SNPs of 25 SNPs were located in 13 protein-coding genes. Five of these identified genes contained more than one SNP. We found that 11 of the 13 genes associated with EBV were associated with muscle. Of the 11 genes related to muscle, six play a role in myogenesis. These six genes are *GXYLT2*, SHQ1 homolog, Saccharomyces cerevisiae (*SHQ1*), *PDZRN3*, ADP-ribosylation factor-like 15 (*ARL15*), oxysterol binding protein 2 (*OSBP2*), and mevalonate kinase (*MVK*).

GXYLT2 encodes the 37.4-kDa proteoglycan core protein, glucoside xylosyltransferase 2. Proteoglycans, one of the macromolecule groups in the extracellular matrix, impact the regulation of muscle cell proliferation and differentiation during myogenesis ([@b37-ajas-28-6-771]). The fact that the SNP with the most significant p-value was located in the intron of *GXYLT2* suggests that this gene is a likely to be associated with racing performance ([Figure 3](#f3-ajas-28-6-771){ref-type="fig"}). SHQ1 encodes an assembly factor required for the assembly of telomerase RNPs ([@b7-ajas-28-6-771]). [@b25-ajas-28-6-771] showed that the telomerase activity in muscle stem cells is retained in old and age-specific telomere shortening and is not detected in the old differentiated muscle fibers in other mammals ([@b25-ajas-28-6-771]). In addition, the second and fifth most significant SNPs, BIEC2_330725 and BIEC2_330739, respectively were located near the *SHQ1* gene ([Figure 3](#f3-ajas-28-6-771){ref-type="fig"}). [@b19-ajas-28-6-771] suggested that PDZRN3 plays an crucial role in the differentiation of myoblasts into myotubes by acting of myogenin ([@b19-ajas-28-6-771]). PDZRN3 contains four significant SNPs in the 3.6-Mb region on chromosome 16 ([Figure 3](#f3-ajas-28-6-771){ref-type="fig"}). Two significant SNPs were found in the ARL15 gene on chromosome 21, which encodes the ADP-ribosylation factor-like 15. ADP-ribosylation factor is reported to be critical regulator of myoblast fusion ([@b1-ajas-28-6-771]) ([Supplementary Figure 1](#s1-ajas-28-6-771){ref-type="supplementary-material"}). OSBP2 encodes oxysterol binding protein 2 and is highly regulated during transitional-phase post-differentiation induction during myogenic differentiation ([@b33-ajas-28-6-771]) ([Supplementary Figure 4](#s1-ajas-28-6-771){ref-type="supplementary-material"}). Therefore, before oxyterol operation, mevalonate kinase (encoded by *MVK* gene) which is an intermediate substance of the oxysterol synthesis pathway may be important in myogenesis ([@b20-ajas-28-6-771]) ([Supplementary Figure 5](#s1-ajas-28-6-771){ref-type="supplementary-material"}).

Five other genes identified in this study are related to muscle maintenance. The five genes include contactin 3 (*CNTN3*); Chaperonin Containing TCP1, Subunit 5 (*CCT5*); valyl-tRNA synthetase 2, mitochondrial (*VARS2*) and inositol polyphosphate-5-phosphatase J (*INPP5J*), Protein Phosphatase 4, Regulatory Subunit 2 (*PPP4R2*). The CNTN3 encodes contactin 1 protein, which is a member of the immunoglobulin superfamily. [@b15-ajas-28-6-771] defined a set of tendon-selective genes present in both adult rat and human tendons that contained CNTN3 ([@b15-ajas-28-6-771]). Tendon connects muscle to bone, so plays a crucial role in muscle functions. Two SNPs were located in the *CNTN3* gene on chromosome 16 ([Figure 3](#f3-ajas-28-6-771){ref-type="fig"}). Two SNPs were also found in the *CCT5* gene on chromosome 21. TCP-1 Ring Complex encoded CCT is known to play a synergistic role in the process of actin folding ([@b17-ajas-28-6-771]). VARS2 encodes valyl-tRNA synthetase 2. Phosphorylation of aminoacyl-tRNA synthetases could play a role in the regulation of protein synthesis in a similar manner as insulin regulates muscle ([@b18-ajas-28-6-771]). INPP5J encodes inositol polyphosphate 5-phosphatase J; its role as a second messenger in signal transduction has been well established in many cell types involved in skeletal muscle signaling ([@b22-ajas-28-6-771]). *PPP4R2* is important partner of survival of motor neuron (SMN) protein which affect modulation of skeletal muscle ([@b3-ajas-28-6-771]).

Comparison of previously reported polymorphisms associated with racing performance
----------------------------------------------------------------------------------

[@b11-ajas-28-6-771] and [@b2-ajas-28-6-771] previously reported a peak of association with best race distance on chromosome 18, and each identified the most important SNPs as BIEC2-417495 ([@b14-ajas-28-6-771]) and BIEC2-417274 ([@b2-ajas-28-6-771]), respectively. These two SNPs did not exceed the threshold genome-wide significance criteria (p-value = 0.000632911, equivalent to p = 0.1 after Bonferroni correction) in stage 1 of this study. However, we tested the relationship of these SNPs with EBV once more for comparison with our result in the second stage. Two reported SNPs reached the threshold in the joint analysis of this study ([Figure 2](#f2-ajas-28-6-771){ref-type="fig"} and [Table 1](#t1-ajas-28-6-771){ref-type="table"}). Moreover, LD blocks across a 1.7-Mb region on chromosomes in a study by [@b11-ajas-28-6-771] were almost identical to the LD blocks using our stage 1 data ([@b13-ajas-28-6-771]) ([Figure 4](#f4-ajas-28-6-771){ref-type="fig"}).

Evaluation of single-nucleotide polymorphisms effects on estimated breeding value
---------------------------------------------------------------------------------

Using the results of the linear regression model, we wanted to identify 28 SNP effects in this study. To evaluate the effects of 28 significant SNPs and compared them with the two SNPs of MSTN, we made 30 plots for the effect allele score with EBV ([Figures 5](#f5-ajas-28-6-771){ref-type="fig"} to [6](#f6-ajas-28-6-771){ref-type="fig"}, [Supplementary Figures 7 to 10](#s1-ajas-28-6-771){ref-type="supplementary-material"}). For each subject in this population, each minor allele was scored for the EBV. Each box plot shows the relationship between the effect allele number and EBV. Each allele had either a positive or negative effect on the racing performance of Thoroughbreds. In chromosome 16, all 12 SNPs had a positive effect on racing performance ([Figure 5](#f5-ajas-28-6-771){ref-type="fig"}). In other chromosomes, nine out of 15 SNPs had positive effects while the remaining seven had negative effects. ([Supplementary Figures 7 to 10](#s1-ajas-28-6-771){ref-type="supplementary-material"}). Both SNPs related to MSTN showed a negative effect on the EBV ([Figure 6](#f6-ajas-28-6-771){ref-type="fig"}).

DISCUSSION
==========

To identify SNPs underlying the racing performance in Thoroughbred, we applied a two-stage GWAS to search for genetic variants associated with the EBV for race time. We present the results of a joint-analysis of two-stage GWAS involving 1,156 Thoroughbreds. In the first stage of our GWAS, a relatively large number of markers were evaluated in a relatively small number of samples. In the second stage, a relatively small number of markers with large effects were evaluated in a much larger number of samples. In data set of the first and second stage were combined in a joint analysis to increase the power to detect genetic associations ([@b31-ajas-28-6-771]; [@b32-ajas-28-6-771]). Using this approach, we identified 28 SNPs associated with racing performance. The SNPs were in genes related to myogenesis and muscle maintenance that have not been previously reported.

Various racing traits such as race time, best race time, rank, starting position, and annual earnings are used to measure racing performance. Out of these, race time of each race is the most direct measure of speed and a suitable quantitative measure for evaluating the racing performance of horses ([@b21-ajas-28-6-771]). However, racing performance is a complex phenotype affected by a variety of different factors such as management of Thoroughbreds, climate, geographical region, age, and reproductive status. In addition, management of exercise conditioning and nutrition has been shown to account for about 65% of racing capacity in the development of elite Thoroughbreds. Even considering these factors, previous studies show that race time had a heritability in the range of 0.1 to 0.3. Also, a significant proportion of variation in athletic ability has been shown to be heritable ([@b5-ajas-28-6-771]).

In animal breeding, EBV is used to rank breeding stock for selection as it only considers the genetic effect on phenotype and predicts the genetic value of an individual based on the phenotypes measured in their relatives. Breeding value is the sum of gene effects of an animal as measured by the performance of its progeny. To exclude other effects and increase the power of the analysis, we calculated a composite phenotype for genetic merit (i.e., EBV) of race time. Each Thoroughbred racehorse has multiple records for race time and each record was achieved under different conditions and environment factors. This makes using race time as a phenotypic value for GWAS difficult. As EBV is a single numerical prediction value that indicates how each Thoroughbred contributes to its progeny, it is suitable as a phenotype for GWAS. However, with the use of EBV as a phenotype in GWAS, inflation becomes a problem.

To investigate the population stratification in stage 1 data, we calculated the lambda value by the statistical package R. The lambda value of stage 1 data was 1.38, which is much higher than that of other studies. The inflation of significant association signals most likely resulted from the relatedness of the horses studied, which contain a massively structured population and high LD. In addition, because EBV comprises only genetic factors, the inflation value increases more than expected. However, inflation is a normal phenomenon in animal GWASs and not a problem for detecting significant SNPs. We excluded relatedness from race time as much as possible by using the EBV and conducted stringent multiple testing (Bonferroni correction) to reduce false-positive errors. Moreover, we performed association analysis using a combined dataset in stage 2 to detecting significant SNPs.

We carried out a two-stage GWAS to search for common variants associated with EBV for race time. GWAS is a promising method to discover common genetic variants that could explain diseases or economic phenotypes of animals and plants. Due to the high cost of genotyping, often a two stage design is used, in which a portion of the sample is genotyped on a large number of markers in stage 1 and a certain number of these markers are followed-up by genotyping the remaining samples in stage 2. Compared with one-stage designs that genotype all samples on all markers, well-constructed two-stage association designs maintain power and reduce cost ([@b34-ajas-28-6-771]). Most often, two-stage design is used to include a replication study in the second stage to define the findings that reach statistical thresholds. We used an alternative strategy, in which the second stage analysis was a joint analysis that combines the data from both stages. This increases the power to detect genetic association ([@b31-ajas-28-6-771]). [@b31-ajas-28-6-771] reported that joint analysis is far more powerful than replication-based analysis ([@b31-ajas-28-6-771]) and recommended this strategy for two-stage GWAS studies that genotype a large portion of the samples in stage 1 and genotype a large portion of SNPs in stage 2. In this study, the number of selected markers in stage 2 was smaller than expected. However, as Thoroughbreds have stronger and larger LD than other species because of selective breeding over the three centuries, a small portion of the markers still retained power in the joint analysis stage. This indicated that a low number of markers could explain large regions of the genome. Our study was sufficiently powered to reliably detect SNPs moderately associated with the racing performance of Thoroughbreds.

Twenty-eight loci of the studied clearly achieved a genome-wide level of significance. This contrasts with GWASs in other phenotypes linked to racing performance such as racing distance, where the most associated SNP related to MSTN had a p-value of \<1.61×10^−9^ ([@b13-ajas-28-6-771]). The most significant SNP in our study had a P-value of \<8.9×10^−8^, and 28 SNPs exceeded the threshold after multiple testing. However, no overlap was observed between the results of this study and those of previously published horse GWAS studies ([@b8-ajas-28-6-771]; [@b11-ajas-28-6-771],[@b12-ajas-28-6-771],[@b13-ajas-28-6-771]). In previous studies, rare mutations with large effects on the racing performance of Thoroughbreds have been identified in genes such as MSTN. Several possible explanations exist for this discrepancy in the results. Tens of thousands of tests performed in GWASs increases the likelihood that associated SNPs in the initial genome-wide scan represent false-positives arising by chance. Another possible explanation for this lack of overlap may be that EBV is a more directly related to phenotype, which would significantly expand the power of GWASs. The identification of multiple SNPs involved in disparate biological pathways supports this notion.

In humans, numerous GWAS and candidate gene studies have revealed more than 220 gene loci ([@b4-ajas-28-6-771]) that influence athletic performance. This hints at the fact that racing performance has the potential to be a polygenic in nature. However in Thoroughbreds only a small number of racing performance-associated sequence variants have been reported ([@b8-ajas-28-6-771]; [@b11-ajas-28-6-771],[@b12-ajas-28-6-771],[@b13-ajas-28-6-771]).

In this study, SNPs were identified in genes with diverse functions related to those previously identified as being selected in the Thoroughbred. [@b9-ajas-28-6-771] indicated that genomic regions containing genes responsible for other biological functions such as insulin signaling, fatty acid metabolism, steroid metabolic processes, and muscle strength have been selected for during the development of the Thoroughbred ([@b9-ajas-28-6-771]). INPP5J in chromosome 8 revealed that these enzymes regulate insulin signaling ([@b27-ajas-28-6-771]). In addition, VARS2 could play a role in the regulation of protein synthesis such as that in muscle by insulin. MVK, encoding mevalonate kinase, is a part of the mevalonate pathway, which is involved in steroid biosynthesis ([@b6-ajas-28-6-771]). A GWAS revealed variants in ARL15 that influence adiponectin levels involved in fatty acid breakdown ([@b30-ajas-28-6-771]).

Due to the *a priori* hypothesis of the candidate gene approach, we did not perform direct experimental evaluation of genes with racing performance-associated SNPs ([@b16-ajas-28-6-771]). The results of this study are important in that they reveal many SNPs that are associated with racing performance. Assuming that the significant variants identified in this study are truly associated with the EBV for race time, we investigated the LD block that includes the genes identified in this study. Next, assuming that LD is significant with racing performance of Thoroughbreds, we speculated that these genes are strong candidates for racing performance of Thoroughbreds. However, these biological hypotheses should be interpreted cautiously as simply the genes that are closest to the significant SNPs. In our study significant SNPs may affect the expression of cis genes up to 10 kb away or act in trans to alter gene expression on other chromosomes ([@b24-ajas-28-6-771]). Also the SNPs could alter the function or tissue-specific expression of a previously unidentified microRNA or genetic element. Therefore we used two indirect evaluations for our study. The first was the addition of two reported SNPs related to MSTN in the joint analysis. Based on previous candidate gene approach, SNPs, BIEC2-417495, and BIEC2-417274, near the equine *MSTN* gene were found to have a highly significant association with racing performance in Thoroughbreds ([@b2-ajas-28-6-771]; [@b14-ajas-28-6-771]). Several MSTN variants are likely to be responsible for large amounts of the phenotypic variance. In domestic animals' traits, few quantitative trait loci have been shown to have large effects on the phenotype. For example, most of the morphological traits across domestic dog breeds and the double-muscling gene in cattle are based on few SNPs. In addition, several GWASs confirmed that SNPs within or near the *MSTN* gene are strongly associated with racing performance in Thoroughbreds ([@b2-ajas-28-6-771]; [@b13-ajas-28-6-771]; [@b36-ajas-28-6-771]; Tozaki et al., 2011). This region contained BIEC2-417495, BIEC2-417274, and the top SNP (g.66493737C\>T) associated with optimum race distance according to [@b11-ajas-28-6-771] ([@b13-ajas-28-6-771]). These SNPs are related to MSTN, which is a member of the transforming growth factor β family expressed in skeletal muscle and acts as a negative regulator of the proliferation and differentiation of myocytes ([@b13-ajas-28-6-771]).

However racing performance is more likely to be polygenic in nature. In this study all p-values of the 28 selected SNPs were more significant than the two previously identified SNPs related to MSTN. Therefore we consider that the 28 SNPs of this study are as important as or more so than those two reported SNPs. The second indirect evaluation was a display of relationships between EBV and effect allele number. We noted that the two SNPs related to MSTN have a negative effect. Thoroughbreds with one or two of these SNPs could produce about 0.5-second faster progeny than those with no SNPs ([Figure 5](#f5-ajas-28-6-771){ref-type="fig"}). The 28 SNPs identified in this study had similar or steeper slopes for racing performance than MSTN SNPs. Thus, we speculated that the 28 SNPs identified in this study influences the racing capacity of Thoroughbreds.

The two-stage GWAS of this study conducted in a large population of Thoroughbreds suggested the presence of 17 protein coding genes related to muscle based on 28 SNPs associated with EBV for race time. Our results strongly support a major involvement of myogenesis in the genetic predisposition for high race performance and suggest several genes as genetic factors for muscle maintenance. These candidate genes may provide insights into the genetic secrets underlying the racing performance of Thoroughbreds.

Supplementary Data
==================

![Manhattan plot of genome-wide association with the estimated breeding value for race time (Stage 1). In this plot, results are plotted as negative log-transformed p-values from the genotypic association test (observed −log 10 p-values by position); the red horizontal dotted line indicates p = 2.41×10^−6^ which means p = 0.05 after Bonferroni correction.](ajas-28-6-771f1){#f1-ajas-28-6-771}

![Manhattan plot of genome-wide association with the estimated breeding value for race time (Stage 1). In this plot, results are plotted as negative log-transformed p-values from the genotypic association test (observed −log 10 p-values by position); Result of stage 1 is shown in two different gray colors. Odd chromosome numbers are in dark grey, and even chromosome numbers in light grey. The red horizontal dotted line indicates stage 2 threshold. Single-nucleotide polymorphisms (SNPs) in stage 2 are shown in two red colors. Significant SNPs with a p-value less than threshold are in red, and others are in light red. Reported SNPs that associated with racing performance of Thoroughbred are in blue.](ajas-28-6-771f2){#f2-ajas-28-6-771}

![Location of the association signal and pairwise linkage disequilibrium (LD) surrounding the most associated SNPs on chromosome 16:14.18--17.79 Mb. LD pattern is depicted using stage 1 data. Association signals are shown for all single-nucleotide polymorphisms (SNPs) genotyped in stage 1 samples (green circles, n = 240); significant SNPs in combined dataset of stage 2 (red diamond, n = 1,156). This region has six nearest genes related to significant SNPs. The most associated SNP, BIEC2-330691, lies in the gene *GXYLT2* and are in small LD. Four SNPs lies in the gene *PDZRN3* and are in almost complete LD. *GXYLT2*, glucoside xylosyltransferase 2; *PDZRN3*, PDZ domain-containing ring finger 3.](ajas-28-6-771f3){#f3-ajas-28-6-771}

![Location of the association signal and pairwise linkage disequilibrium (LD) surrounding two reported single-nucleotide polymorphisms (SNPs) related to gene myostatin. LD pattern is depicted using stage 1 data (n = 240). Association signals of two SNPs are shown in combined dataset of stage 2 (red diamond, n = 1,156).](ajas-28-6-771f4){#f4-ajas-28-6-771}

![Boxplots show cumulative effect for estimated breeding value of the effect allele number of significant 12 single-nucleotide polymorphisms (SNPs) on chromosome 16. All 12 SNPs on chromosome 16 have positive effects.](ajas-28-6-771f5){#f5-ajas-28-6-771}

![Boxplots show cumulative effect for estimated breeding value of the effect allele number of significant 2 single-nucleotide polymorphisms (SNPs) near myostatin. These two SNPs have negative effects.](ajas-28-6-771f6){#f6-ajas-28-6-771}

###### 

List of SNPs with a p-value of \<0.000632911 (equivalent to p = 0.1 after Bonferroni correction) based on the linear regression model of stage 2 data (n = 1,156)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                  Chr   BP         Neareat gene\          SNP type     Minor allele   Major allele   Stage 1     Stage 2                                    
                                   (Ensemble gene ID)                                                                                                       
  --------------- ----- ---------- ---------------------- ------------ -------------- -------------- ----------- --------- ----------- ----------- -------- --------
  BIEC2_906777    5     40747218   \-\                    InterGenic   A              G              1.63.E-04   0.356     0.278       8.38.E-05   0.330    0.141
                                   (ENSECAG00000019204)                                                                                                     

  BIEC2_1026019   8     5906904    INPP5J\                InterGenic   A              G              1.64.E-05   0.159     −0.4315     1.73.E-04   0.190    −0.163
                                   (ENSECAG00000006664)                                                                                                     

  BIEC2_1026200   8     6126833    OSBP2\                 InterGenic   G              A              1.06.E-05   0.107     −0.5102     1.28.E-05   0.142    −0.215
                                   (ENSECAG00000015443)                                                                                                     

  BIEC2_1029757   8     11590300   MVK\                   InterGenic   C              A              1.75.E-05   0.119     −0.4715     8.85.E-06   0.137    −0.219
                                   (ENSECAG00000023067)                                                                                                     

  BIEC2_330101    16    14185461   \-                     InterGenic   C              A              1.39.E-04   0.254     0.3328      4.29.E-06   0.216    0.195

  BIEC2_330360    16    15550375   \-                     InterGenic   A              G              8.12.E-04   0.388     0.2536      2.00.E-06   0.371    0.167

  BIEC2_330495    16    16289366   CNTN3\                 Genic        A              G              3.81.E-04   0.298     0.2847      1.91.E-04   0.271    0.143
                                   (ENSECAG00000013575)                                                                                                     

  BIEC2_330509    16    16334663   InterGenic             G            A              4.43.E-04      0.297       0.2818    8.79.E-05   0.274       0.150    

  BIEC2_330558    16    16948655   PDZRN3\                Genic        G              A              6.02.E-04   0.377     0.2565      2.28.E-05   0.362    0.150
                                   (ENSECAG00000014864)                                                                                                     

  BIEC2_330572    16    16993987   Genic                  A            G              7.93.E-04      0.367       0.2484    4.53.E-05   0.358       0.145    

  BIEC2_330575    16    16999220                          Genic        A              G              2.32.E-04   0.354     0.2734      1.73.E-04   0.339    0.134

  BIEC2_330578    16    17001997                          Genic        G              A              6.02.E-04   0.377     0.2565      1.92.E-05   0.363    0.152

  BIEC2_330677    16    17421511   PPP4R2\                Genic        A              G              6.13.E-04   0.377     0.2562      2.66.E-05   0.359    0.149
                                   (ENSECAG00000000689)                                                                                                     

  BIEC2_330691    16    17546589   GXYLT2\                Genic        G              A              7.05.E-04   0.371     0.2611      8.94.E-08   0.355    0.191
                                   (ENSECAG00000008483)                                                                                                     

  BIEC2_330725    16    17763943   SHQ1\                  InterGenic   G              A              4.49.E-04   0.325     0.2802      9.40.E-07   0.316    0.180
                                   (ENSECAG00000015673)                                                                                                     

  BIEC2_330739    16    17790340   InterGenic             G            A              6.71.E-04      0.315       0.2672    2.97.E-06   0.310       0.172    

  BIEC2_527753    20    29897398   VARS2\                 Genic        A              G              4.60.E-04   0.219     0.3011      1.32.E-05   0.172    0.195
                                   (ENSECAG00000018202)                                                                                                     

  BIEC2_527879    20    30126579   \-\                    InterGenic   A              G              4.60.E-04   0.219     0.3011      6.86.E-06   0.172    0.202
                                   (ENSECAG00000015285)                                                                                                     

  BIEC2_529755    20    32127869   \-\                    InterGenic   A              C              5.23.E-04   0.256     0.2969      3.80.E-05   0.210    0.171
                                   (ENSECAG00000017401)                                                                                                     

  BIEC2_529760    20    32131071   InterGenic             C            A              2.39.E-04      0.296       0.2909    4.09.E-06   0.239       0.180    

  BIEC2_554645    21    18154976   ARL15\                 Genic        A              G              1.98.E-05   0.218     −0.3696     7.44.E-06   0.213    −0.188
                                   (ENSECAG00000014970)                                                                                                     

  BIEC2_554739    21    18348602   InterGenic             C            A              9.53.E-05      0.265       −0.3267   1.94.E-04   0.256       −0.146   

  BIEC2_568963    21    47502588   \-                     InterGenic   A              G              4.70.E-04   0.471     −0.2539     1.98.E-05   0.474    −0.149

  BIEC2_569862    21    48967346   CCT5\                  InterGenic   G              A              2.59.E-04   0.373     −0.2739     2.57.E-06   0.381    −0.165
                                   (ENSECAG00000019192)                                                                                                     

  BIEC2_570062    21    49384234   Genic                  A            C              1.30.E-04      0.404       0.2819    2.12.E-04   0.386       0.127    

  BIEC2_570485    21    49894191   TAS2R1\                InterGenic   A              G              3.40.E-04   0.215     0.3012      3.48.E-04   0.209    0.148
                                   (ENSECAG00000005160)                                                                                                     

  BIEC2_732151    28    17405077   \-                     InterGenic   A              C              7.52.E-05   0.290     0.3151      4.42.E-04   0.274    0.134

  BIEC2_814518    30    3869336    RGS7\                  InterGenic   A              G              2.33.E-05   0.388     0.3152      5.79.E-04   0.390    0.119
                                   (ENSECAG00000009422)                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

BP, biological process; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
